Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for China Pharma Holding's Debt-to-EBITDA or its related term are showing as below:
STU:XQJ'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.45 Med: -0.87 Max: 579.25
Current: -3.17
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Pharma Holding was 579.25. The lowest was -10.45. And the median was -0.87.
STU:XQJ's Debt-to-EBITDA is ranked worse than 100% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs STU:XQJ: -3.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Pharma Holding Debt-to-EBITDA Related Terms
China Pharma Holding Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:XQJ vs INCR, TLPH, CTOR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
China Pharma Holding (STU:XQJ) has a Debt-to-EBITDA of -7.01 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Pharma Holding. According to the industry distribution chart, China Pharma Holding ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is China Pharma Holding's Debt-to-EBITDA too high?
China Pharma Holding's current Debt-to-EBITDA is -7.01. Based on the distribution chart, China Pharma Holding ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Pharma Holding has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Debt-to-EBITDA compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #999999 out of 682 companies for Debt-to-EBITDA. This places China Pharma Holding in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Pharma Holding. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Debt-to-EBITDA is -7.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Debt-to-EBITDA of -7.01. The stock's GF Value™ is €5.69, compared to a current price of €26.80 — trading 371% above its estimated fair value. The current Debt-to-EBITDA is -7.01. China Pharma Holding's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Debt-to-EBITDA is -7.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 371% above its estimated GF Value™ of €5.69.
Key valuation signals for STU:XQJ:
Debt-to-EBITDA: -7.01
GF Value™: €5.69 vs. price of €26.80 (371% above fair value)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
22GF Score
Get the complete analysis for STU:XQJ
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
